WarfarinPharmacogeneticsVitamin K Epoxide ReductasesAnticoagulantsMixed Function OxygenasesAryl Hydrocarbon HydroxylasesIndividualized MedicineInternational CooperationCytochrome P-450 CYP2D6Polymorphism, GeneticGenotypeProthrombin TimeHemorrhageBiomarkers, PharmacologicalThromboembolismAtrial FibrillationMicrobial ConsortiaPolymorphism, Single Nucleotidebeta-AlanineDrug-Related Side Effects and Adverse ReactionsVitamin KDrug Dosage CalculationsInternational AgenciesPharmaceutical PreparationsDrug InteractionsGenetic VariationRodenticidesGenetic TestingDrug TherapyCytochrome P-450 Enzyme SystemMetabolic Detoxication, DrugTreatment OutcomePharmacy ResidenciesAcenocoumarolDose-Response Relationship, DrugStrokeDihydrouracil Dehydrogenase (NADP)InternationalityDrug MonitoringMethyltransferasesAspirinVitamin K 1Platelet Aggregation InhibitorsCytochrome P-450 CYP3ARisk FactorsGenome-Wide Association StudyClinical Trials as TopicInternational Normalized RatioPhenotypeDrug DesignPharmacokineticsUnited StatesAllelesGene Frequency4-HydroxycoumarinsCohort StudiesBlood CoagulationIntracranial HemorrhagesGenetic Predisposition to DiseaseRisk AssessmentBenzimidazolesAzathioprine6-MercaptopurineGenome, HumanGlucuronosyltransferaseSleep Arousal DisordersAdministration, OralOrganic Anion TransportersCodeineStevens-Johnson SyndromeBiotransformationEmbolismHaplotypesDrug ResistanceNeoplasmsAntipsychotic Agents